期刊文献+

纳米颗粒的体内药代动力学及其影响因素 被引量:1

Pharmacokinetics of nanoparticles in vivo and its influence factors
下载PDF
导出
摘要 纳米颗粒的体内生物安全性是目前纳米技术研究领域的热点问题,对于纳米颗粒在生物医药应用时是否会产生纳米毒性为众多学者所关注。纳米颗粒的体内代谢动力学表现是影响其体内纳米毒性的主要因素,而纳米颗粒的一些理化性能(如大小、电荷和表面性质)也会直接影响到其体内代谢动力学过程。本文将就纳米颗粒体内代谢动力学特点及其影响因素进行综述,为纳米颗粒体内生物安全性评价提供理论依据。
作者 谢广平 孙皎
出处 《口腔材料器械杂志》 2010年第1期23-25,33,共4页 Chinese Journal of Dental Materials and Devices
基金 上海市重点学科建设项目(项目编号:S30206) 上海市科委项目(0752nm026 08DZ2291600)
  • 相关文献

参考文献27

  • 1Hughes GA. Nanostrueture-mediated drag delivery. Nanomedicine 2005; 1 (1): 22-30. eng.
  • 2Maynard AD, Aitken RJ, Butz T, Colvin V, Donaldson K, Oberdorster G, et al. Safe handling of nanoteehnology. Nature 2006; 444 (7117) : 267 -9.
  • 3Tsuji JS, Maynard AD, Howard PC, James JT, Lain CW, Warheit DB, et al. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles. Toxicol Scl 2006; 89 (1): 42 -50.
  • 4Wang JJ, Sanderson B J, Wang H. Cyto-and genotoxicity of ultrafine TiO2 particles in cuhured human lymphoblastoid cells. Mutat Res 2007; 628 (2): 99- 106. eng.
  • 5Colvin VL. The potential environmental impact of engineered nanomaterials. Nat Biotechnol 2003 ; 21 (10) : 1166 -70.
  • 6Fischer HC, Chan WC. Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol 2007 ; 18 (6) : 565 - 71.
  • 7Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving flom studies of uhrafine particles. Environ Health Perspect 2005; 113 (7) : 823 ~ 39.
  • 8Li SD, Huang L. Pharmacokinelics and biodistribution of nanoparticles. Mol Pharm. 2008; 5 (4): 496-504.
  • 9Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56 ( 11 ) : 1649 -59.
  • 10Saba TM. Physiology and physiopathology of the reticuloendothelial system. Arch Intern Med 1970; 126 (6) : 1031 -52.

同被引文献13

  • 1JiangY,ZhangY,LuanJ,DuanH,ZhangF,YagasakiK,ZhangG.Effectsofbufalinontheproliferationofhuman lung cancer cells and its molecular mechanisms o~ action. Cytotechnology. 2010; 62(6): 573-583.
  • 2Xie CM, Chan WY, Yu S, Zhao J, Cheng CH. Bufalin induces autophagy-mediated cell death in human colon cancer ceils through reactive oxygen species generation and JNK activation. Free Radic Biol Med. 2011; 51 (7) : 1365-1375.
  • 3Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M, Tang W. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 2010; 11(3): 342-349.
  • 4苏永华,凌昌全.蟾毒灵白蛋白纳米粒制剂及其制备方法.中国,200510110061.4.2006-05-17.http://211.157.104.87:8080/sipo/zljs/hyjmy'x-new.jsp?recid=CN200510110061.4&lei)(in-fHlzl&title一蟾毒灵白蛋白纳米粒制剂及其制备方法&ipc=A61K38/38(2006.01)I.
  • 5孙宁.生物样品中MCC一555定量分析及临床前药代动力学与毒代动力学研究.上海:第二军医大学.2006:32-33.
  • 6Cao Y, Zhao L, Liang Q, Bi K, Wang Y, Luo O. Study of the determination and pharmacokinetics of bufadienolides in dog's plasma after administration of Liu Shen-Wan by high performance liquid chromatography time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 853(12): 227-233.
  • 7Zhang Y, Tang X, Liu X, Li F, Lin X. Simultaneous determination of three bufadienolides in rat plasma after intravenous administration of bufadienolides extract by ultra performance liquid chromatography electrosprayionization tandem mass spectrometry. Anal Chim Acta. 2008; 610(2): 224-231.
  • 8Liang Y, Liu AH, Qin S, Sun JH, Yang M, Li P, Guo DA. Simultaneous determination and pharmacokinetics of five bufadienolides in rat plasma after oral administra tion of Chansu extract by SPE-LC method. J Pharm Biomed Anal. 2008; 46(2): 442-448.
  • 9《化学药物非临床药代动力学研究技术指导原则》课题研究组.化学药物非临床药代动力学研究技术指导原则.EH3GPT5-1.2005.
  • 10王炎,李琦,曹伟家.纳米中药治疗肿瘤的研究[J].中西医结合学报,2007,5(6):697-701. 被引量:4

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部